1101 related articles for article (PubMed ID: 22611005)
1. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
[TBL] [Abstract][Full Text] [Related]
2. Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Bardani E; Nicolaides KH
Ultrasound Obstet Gynecol; 2020 Sep; 56(3):408-415. PubMed ID: 32621353
[TBL] [Abstract][Full Text] [Related]
3. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
4. Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-trimester screening for trisomy 21.
Wright D; Abele H; Baker A; Kagan KO
Ultrasound Obstet Gynecol; 2011 Sep; 38(3):309-13. PubMed ID: 21400623
[TBL] [Abstract][Full Text] [Related]
5. Prospective validation of first-trimester combined screening for trisomy 21.
Kagan KO; Etchegaray A; Zhou Y; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2009 Jul; 34(1):14-8. PubMed ID: 19526452
[TBL] [Abstract][Full Text] [Related]
6. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
Wright D; Spencer K; Kagan K K; Tørring N; Petersen OB; Christou A; Kallikas J; Nicolaides KH
Ultrasound Obstet Gynecol; 2010 Oct; 36(4):404-11. PubMed ID: 20658511
[TBL] [Abstract][Full Text] [Related]
7. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
8. Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies.
Zaragoza E; Akolekar R; Poon LC; Pepes S; Nicolaides KH
Ultrasound Obstet Gynecol; 2009 Apr; 33(4):382-6. PubMed ID: 19277983
[TBL] [Abstract][Full Text] [Related]
9. First trimester maternal serum placental growth factor in trisomy 21 pregnancies.
Cowans NJ; Stamatopoulou A; Spencer K
Prenat Diagn; 2010 May; 30(5):449-53. PubMed ID: 20301202
[TBL] [Abstract][Full Text] [Related]
10. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
11. Maternal serum placental growth factor in prospective screening for aneuploidies at 8-13 weeks' gestation.
Pandya P; Wright D; Syngelaki A; Akolekar R; Nicolaides KH
Fetal Diagn Ther; 2012; 31(2):87-93. PubMed ID: 22286035
[TBL] [Abstract][Full Text] [Related]
12. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
13. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
[TBL] [Abstract][Full Text] [Related]
14. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
[TBL] [Abstract][Full Text] [Related]
15. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia.
Wortelboer EJ; Koster MP; Cuckle HS; Stoutenbeek PH; Schielen PC; Visser GH
BJOG; 2010 Oct; 117(11):1384-9. PubMed ID: 20840693
[TBL] [Abstract][Full Text] [Related]
16. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
[TBL] [Abstract][Full Text] [Related]
17. Routine first-trimester combined screening for pre-eclampsia: pregnancy-associated plasma protein-A or placental growth factor?
Noël L; Guy GP; Jones S; Forenc K; Buck E; Papageorghiou AT; Thilaganathan B
Ultrasound Obstet Gynecol; 2021 Oct; 58(4):540-545. PubMed ID: 33998078
[TBL] [Abstract][Full Text] [Related]
18. Maternal serum placental growth factor, pregnancy-associated plasma protein-a and free β-human chorionic gonadotrophin at 30-33 weeks in the prediction of pre-eclampsia.
Lai J; Pinas A; Poon LC; Agathokleous M; Nicolaides KH
Fetal Diagn Ther; 2013; 33(3):164-72. PubMed ID: 23445908
[TBL] [Abstract][Full Text] [Related]
19. Modeling Down syndrome screening performance using first-trimester serum markers.
Koster MP; Wortelboer EJ; Stoutenbeek P; Visser GH; Schielen PC
Ultrasound Obstet Gynecol; 2011 Aug; 38(2):134-9. PubMed ID: 21800388
[TBL] [Abstract][Full Text] [Related]
20. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
